Annals of Hematology

, Volume 89, Issue 6, pp 563–568

Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study

  • Sung Yong Oh
  • Won Seog Kim
  • Jin Seok Kim
  • Seok Jin Kim
  • Hyuk-Chan Kwon
  • Dae Ho Lee
  • Jong Ho Won
  • In Gyu Hwang
  • Min Kyoung Kim
  • Soon Il Lee
  • Yee Soo Chae
  • Deok-Hwan Yang
  • Gyeong-Won Lee
  • Chul Won Choi
  • Jinny Park
  • Cheolwon Suh
  • Hyo-Jin Kim
Original Article

DOI: 10.1007/s00277-009-0875-7

Cite this article as:
Oh, S.Y., Kim, W.S., Kim, J.S. et al. Ann Hematol (2010) 89: 563. doi:10.1007/s00277-009-0875-7

Abstracts

Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34–79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n = 22), chemotherapy (n = 28), or radiotherapy (n = 6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6–8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease—characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.

Keywords

Pulmonary Marginal zone B-cell lymphoma Chemotherapy 

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sung Yong Oh
    • 1
    • 14
  • Won Seog Kim
    • 2
  • Jin Seok Kim
    • 2
  • Seok Jin Kim
    • 3
  • Hyuk-Chan Kwon
    • 1
    • 14
  • Dae Ho Lee
    • 4
  • Jong Ho Won
    • 5
  • In Gyu Hwang
    • 6
  • Min Kyoung Kim
    • 7
  • Soon Il Lee
    • 8
  • Yee Soo Chae
    • 9
  • Deok-Hwan Yang
    • 10
  • Gyeong-Won Lee
    • 11
  • Chul Won Choi
    • 12
  • Jinny Park
    • 13
  • Cheolwon Suh
    • 4
  • Hyo-Jin Kim
    • 1
  1. 1.Department of Internal MedicineDong-A University College of MedicineSeo-guKorea
  2. 2.Division of Hematology/Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Department of Internal MedicineYonsei University College of MedicineSeoulKorea
  4. 4.Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  5. 5.Department of Internal MedicineUniversity College of Medicine, Soon Chun Hyang UniversitySeoulKorea
  6. 6.Division of Hematology–Oncology, Department of MedicineChung-Ang UniversitySeoulKorea
  7. 7.Division of Oncology, Department of Internal MedicineYeungnam University College of MedicineDaeguKorea
  8. 8.Department of Internal MedicineDankook University College of MedicineCheonanKorea
  9. 9.Department of Hematology/OncologyKyungpook National University Hospital, Kyungpook National University School of MedicineDaeguKorea
  10. 10.Department of Hematology–OncologyChonnam National University Hwasun HospitalJeollanam-doKorea
  11. 11.Division of Hematology–Oncology, Department of Internal MedicineCollege of Medicine, Gyeongsang National UniversityJinjuKorea
  12. 12.Division of Oncology -Hematology, Department of Internal MedicineKorea University Anam Hospital, Korea University College of MedicineSeoulKorea
  13. 13.Department of Internal MedicineGachon Medical SchoolInchonKorea
  14. 14.Medical Research Center for Cancer Molecular TherapyDong-A University College of MedicineBusanKorea